ORDER
This mаtter comes before the Court on Plaintiff’s Motion for Remand (doc. 8). The Motion has been briefed and is now ripe for disposition.
I. Background.
Plaintiff, Peyton Powell Brown, brought this action against defendants, Endo Pharmaceuticals, Inc. and Alex Stebbins, in the Circuit Court of Clarke County, Alabama. The Complaint alleged that plaintiff’s decedent, Jason Dewitt Powell, died on March 28, 2012 after crushing and snorting Opana, a tablet form of the prescription painkiller oxymorphone. According to well-pleaded allegations of the Complaint, defendant Endo manufactured these Opana tablets despite knowledge of risks to producing that medication in a form that could be crushed, broken and/or dissolved, thereby releasing high concentrations of oxymorphone and escalating the dangers to the end user. The Complaint alleges that defendant Alex Stebbins (who is alleged to have “previously held a nursing license”) supplied Opana to Powell on March 27, 2012, and that Powell’s ingestion of same caused his death hours later. (See doc. 1, Exh. A, at 9-10.) On the basis of these factual allegations, Brown’s Complaint presented purely state-law claims of negligence and wantonness against Endo and Stebbins, and demanded punitive damages against both defendants pursuant to Alabama’s Wrongful Death Act, as codified at Ala.Code § 6-5-410.
On May 7, 2014, defendant Endo Pharmaceuticals filed a Notice of Removal (doc. 1), removing this action to federal court. The Notice of Removal alleged that “[t]his Court has jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 (federal question jurisdiction) and 1332 (diversity of citizenship).” (Doc. 1, ¶ 1.) As to the former, Endo contended that Brown’s “claims implicate substantial questions of federal law” because (i) they “involve the design, manufacture and distribution of Opana Tablets, a highly regulated Schedule II controlled narcotic substance” and (ii) they “effectively seek[] to challenge the decision by federal regulatory authorities to authorize the manufacture and distribution of Opana non-crush resistant tablets.” (Id., ¶¶ 30 -33.) As to the latter, Endo’s position was that Brown and Endo were of diverse citizenship, and that Stebbins’ non-diverse citizenship (both Brown and Stebbins are identified in the Complaint as Alabama citizens) may be disregarded because he was fraudulently joined. (Id., ¶¶ 9-17.)
Plaintiff has now filed a Motion for Remand, challenging the existence of federal subject matter jurisdiction (under eithеr a federal question or a diversity theory) and seeking remand of this case to Clarke County. For its part, Endo opposes the Motion, arguing that jurisdiction is proper and, alternatively, asking that plaintiffs claims against Stebbins be severed to create diversity of citizenship as to the remaining claims.
II. Analysis.
A.removing defendant must establish the propriety of removal under 28 U.S.C. § 1441 and, therefore, must demon
A. Federal Question Jurisdiction.
As an initial matter, Endo asserts in its Notice of Removal that federal jurisdiction lies pursuant to the federal question provisions of 28 U.S.C. § 1331. (See doc. 1, ¶¶ 1, 28-33.) Federal courts possess “original jurisdiction of all civil actions arising under the Constitution, laws, or treaties of thе United States.” 28 U.S.C. § 1331. “The test ordinarily applied for determining whether a claim arises under federal law is whether a federal question appears on the face of the plaintiffs well-pleaded complaint.” Connecticut State Dental,
That said, even in the absence of a federally created cause of action, “in
The Eleventh Circuit has emphasized, however, that this is a “slim category of cases.” Adventure Outdoors,
Endo maintains that a substantial federal issue is presented here because Brown’s state-law negligence and wantonness claims “depend entirely upon construction and application of the federal Controlled Substances Act (‘CSA’) and its enabling regulations.” (Doc. 12, at 10.) Endo elaborates that “[t]he CSA squarely controls Endo’s duties and constraints with respect to marketing Opana,” and insists that “the CSA creates the sole legal duty governing Plaintiffs claims against Endo.” (Id. at 11.) Defendant’s analysis is long on rhetoric, but short on supporting law, facts and reasoning. "Why is the CSA necessarily the only source of any legal duty of care that Endo might have owed Powell? The Complaint does not identify that statute as the legal foundation of plaintiffs negligence/wantonness claims against Endo.
Even if the issue of duty were controlled by the CSA (and Endo has made no showing that might support such a conclusion), § 1331 jurisdiction would remain inappropriate under the substantiality prong of the Grable test. Again, not just any nexus to federal law (or even the presence of a federal element in a state-law claim) triggers “substantial federal question” jurisdiction. The character of that federal question is of critical importance. Would the CSA Issues ostensibly implicated by Brown’s complaint involve pure questions of unsettled federal law (which might support federal jurisdiction), or would they involve fact-bound application of well-settled legal principles to this case (which would not)?
B. Fraudulent Joinder.
As an additional basis for invoking federal jurisdiction, Endo contends that
As a general proposition, “[diversity jurisdiction requires complete diversity between named plaintiffs and defendants.” Sweet Pea Marine, Ltd. v. AJP Marine, Inc.,
To satisfy this heavy burden, Endo contends that the Complaint does not state a claim against Stebbins because it fails to comport with the heightened pleading requirements of Alabama Code § 6-5-551, which governs wrongful déath actions “against а health care provider for breach of the standard of care.” Id.
Even if § 6-5-551 applied to Brown’s claims against Stebbins (and, again, Endo has not met its burden of establishing that such is the case), it is hardly a slam dunk that the Complaint falls short of this pleading standard. For fraudulent joinder to be rejected as a basis for diversity jurisdiction in a particular case, “all that is necessary is for the Court to find ... that [Endo] has failed to make a clear and convincing showing that no Alabama court could deem [Brown’s] complaint against the non-diverse defendants sufficient under Ala.Code § 6-5-551.” Ash v. Providence Hosp.,
In both its Notice of Removal and its brief on the Motion to Remand, Endo also advances the argument that Stebbins was fraudulently joined because “[i]n Alabama, a plaintiff may not recover in a legal or equitable proceeding when the basis for such an action rests on his or her own illegal conduct.” (Doc. 115; see also doc. 12, at 5 n. 2.)
In briefing the Motion to Remand, Endo formulates another fraudulent joinder argument as to the claims against Stebbins. Specifically, Endo points out that plaintiffs negligence claim against Stebbins requires plaintiff to prove duty, breach of duty and damages. (Doc. 12, at 4.) Under Alabama law, Endo continues, “a nurse may not prescribe Section II narcotic drugs like Opana.” (Id.) Therefore, Endo reasons, plaintiff cannot possibly prove the duty element of her negligence claim аgainst Stebbins because “[ojbviously, a practice that is not permitted by law cannot create a legal duty.” (Id. (emphasis omitted).) Defendant cites no authority for what it terms an “obvious[ ]” proposition.
Insofar as Endo’s position is that an Alabama negligence claim is unsustainable against a defendant who has acted in violation of law, that premise is demonstrably invalid. Alabama courts have held that “[violation of statutes or ordinances may be negligence.... If the statute or ordinance violated was enacted or promulgated for the protection of the person claiming to have been injured by reason of the violation, the violation of the statute may be negligence per se or negligence as
As an alternative to a traditional fraudulent joinder analysis, Endo cites the doctrine of fraudulent misjoinder. In certain circumstances, fraudulent misjoinder of a nondiver se defendant may justify excluding thаt defendant’s citizenship from the § 1332 jurisdictional calculus. See Tapscott v. MS Dealer Service Corp.,
Ask,
C. Severance.
As an alternative ground for opposing remand, Endo argues that even 'if Stebbens was not fraudulently joined and diversity jurisdiction is lacking, “this court can still retain jurisdiction by severing claims against nondiverse dispensable defendants.” (Doc. 1, 18.) The fundamental problem is that Endo essentially is asking this Court to employ the procedural device of severance not to “retain” jurisdiction, but to manufacture federal jurisdiction that did not exist at the moment when Endo removed this case from Clarke County Circuit Court. As shown by the foregoing discussion, when the Notice of Removal was filed, there was neither federal question jurisdiction nor diversity jurisdiction over this action. Of course, well-settled law provides that diversity jurisdiction is examined at the time of removal. See, e.g., Ehlen Floor Covering, Inc. v. Lamb,
Federal courts have frowned on using the Rule 21 severance vehicle to conjure removal jurisdiction that would otherwise be absent. See, e.g., Wolf v. Kennelly,
III. Conclusion.
■ When confronted with a pleading that may or may not provide a basis for federal removal jurisdiction, a defendant must not preemptively remove the case and ask the federal court to resolve those jurisdictional uncertainties in favor of removal because the plaintiff could have drafted her complaint with greater precision and clarity. Rather, the defendant should avail itself of available procedural tools in state court to ferret out and lock in the plaintiffs claims. If discovery materials and refined pleadings establish a substantial federal question or negate the possibility that the plaintiff could prevail in her claims against the non-diverse defendant because of a defect specific to the claims against that defendant, then and only then should the diverse defendant remove the case. Likewise, a defendant convinced that a plaintiff has misjoined a non-diverse defendant should seek severance in state court, not federal court (at least in the absence of an еgregious misjoinder, such as where there is literally no connection between the plaintiffs claims against the two defendants). In other words, a defendant in Endo’s position should ask questions first
Here, Endo elected to remove this case to federal court at a very early stage of the process, even though it is unable to shoulder its heavy burden of establishing either the existence of a substantial federal question or the certainty that Brown’s claims against the non-diverse defendant cannot succeed because of a defect specific to the claims against that defendant. Because the record does not support a determination that either federal question jurisdiction or diversity jurisdiction is present here, Plaintiffs Motion for Remand (doc. 8) is granted. This аction is remanded to the Circuit Court of Clarke County, Alabama for further proceedings.
Notes
. "In a wrongful death action under Alabama law, the only recoverable damages are punitive damages intended to punish the tortfeasor for its actions—not to compensate the plaintiff.” Patterson v. Walden,
. See also Whitt v. Shennan Int’l Corp.,
. To be sure, Paragraphs 10 and 11 of the Complaint include factual allegations regarding Endo's contacts with the Food and Drug Administration ("FDA”), and particularly Endo's purported admissions to the FDA in late 2012 that the non-crush resistant form of Opana tablets (the same form that Powell allegedly ingested) was inherently dangerous, that Endo had developed a new crush resistant form of those tablets in late 2011 or early 2012, and that the FDA slhould forbid generic drug manufacturers from making the non-crush resistant form. (Doc. 1, Exh. A, at 10 ¶¶ 10-11.) The point of these FDA references in the Complaint was not that FDA regulations provide the relevant standard of care or that Endo ever diverged from FDA authorizations or requirements; rather, the obvious utility of those factual allegations to Brown was that they tend to show Endo's awareness of the dangerous' nature of non-crushable Opana and its development of a safer alternative form of the drug months before Powell died by crushing and ingesting Opana in a form that Endo knew to be unsafe. In short, these scant mentions of the FDA in the Complaint are not indicativе of the joinder of a federal issue in this action.
. These principles may be summarized as follows: "[T]he ideal vehicle for finding ... jurisdiction pursuant to the substantial federal question doctrine is a case in which the state-law claims will be resolved by deciding a disputed federal issue that is discrete and purely legal.... [T]o the extent the federal issue in a case is fact-bound—requiring a court [to] apply federal law to the specific facts of a case to decide the state-law claims— it is less likely the case will fit into the small category of cases that may be brought into this Court because they raise a substantial federal question.” Cooper v. International Paper Co.,
.Indeed, the relationship between the CSA and statedaw negligence claims like Brown’s is far from obvious. See, e.g., Little v. Purdue Pharma, L.P.,
. In that respect, this action is analogous to Ash v. Providence Hosp.,
. See Adventure Outdoors,
. That section provides, in part, as follows: "In any action for injury, damages, or wrongful death, whether in contract or in tort, against a health care provider for breach of the standard of care, ... [t]he plaintiff shall include in the complaint filed in the action a detаiled specification and factual description of each act and omission alleged by plaintiff to render the health care provider liable to plaintiff and shall include when feasible and ascertainable the date, time, and place of the act or acts." Ala.Code § 6-5-551.
. See, e.g., Mikkelsen v. Saloma,
. Endo frames this argument in the following terms: "Alabama’s ‘serious misconduct' tort rule аnnounced in Oden will almost certainly bar any claims against Stebbins based on Plaintiff's admitted illegal (felony) misuse of the Opana tablets that are the subject of this action.” (Doc. 1, ¶ 21.).
. See also Walton v. Bayer Corp.,
. The Fifth Circuit has explained this rule as follows: "[W]hen, on a motion to remand, a showing that compels a holding that there is no reasonable basis for predicting that state law would allow the plaintiff to recоver against the in-state defendant necessarily compels the same result for the nonresident defendant, there is no improper joinder; there is only a lawsuit lacking in merit. In such cases, it makes little sense to single out the in-state defendants as 'sham' defendants and call their joinder improper.” Smallwood,
. An example illustrates the point. Suppose there is an automobile accident caused when Driver A and Driver B collide after Driver B abruptly switched lanes without activating his turn signal. That omission by Driver B would violate an Alabama statute. See Ala. Code § 32-5A-133(a) ("No persоn shall turn a vehicle or move right or left upon a roadway unless and until such movement can be made with reasonable safety nor without giving an appropriate signal....”). Under Endo's argument, Driver B would owe no duty to Driv-
. To be sure, Endo has argued that there is "no such nexus” between Brown's claims er A because Alabama drivers are not permitted to change lanes without activating their turn signals and "a practice that is not permitted by law cannot create a legal duty.” (Doc. 12, at 4.) But such a premise appears unfounded in applicable law or common sense. See, e.g., Carroll v. Deaton, Inc.,
. See also Leonard v. Enterprise Rent a Car,
. See also Baker v. Tri-Nations Express, Inc.,
. See also Heard v. American Alternative Ins. Corp.,
